Please login to the form below
US Biomedical Advanced Research and Development Authority
This page shows the latest US Biomedical Advanced Research and Development Authority news and features for those working in and with pharma, biotech and healthcare.
FDA briefing document backs J&J’s one-dose COVID-19 vaccine
In the US, the efficacy rate increased slightly to 72%, while in Latin America and South Africa the vaccine was 66% and 57% effective, respectively. ... Under the terms of the deal, the US Biomedical Advanced Research and Development Authority (BARDA)
Latest news
-
J&J’s one-dose COVID-19 vaccine proves 66% effective in phase 3 trial
In the US, the efficacy rate was 72% while in Latin America and South Africa the vaccine was 66% and 57% effective, respectively. ... Under the terms of the deal, the US Biomedical Advanced Research and Development Authority (BARDA) and the US Department
-
J&J could launch its single-dose COVID-19 vaccine in March
US pharma Johnson &Johnson (J&J) is planning to launch its single-dose COVID-19 vaccine in March, according to the company’s chief scientific officer Paul Stoffels. . ... The phase 3 ENSEMBLE trial was launched in collaboration with the US Department
-
J&J completes enrolment for late-stage COVID-19 vaccine trial
The phase 3 ENSEMBLE trial is being conducted in collaboration with the US Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID). ... This trial is currently enrolling
-
EMA launches rolling review of J&J’s COVID-19 vaccine
The pharma giant is initiating the phase 3 ENSEMBLE trial in collaboration with the US Department of Health and Human Services’ (HHS), Biomedical Advanced Research and Development Authority (BARDA) and the ... US National Institute of Allergy and
-
Regeneron’s COVID-19 antibody cocktail scores FDA emergency approval
A COVID-19 antibody cocktail developed by Regeneron has been given an emergency use authorisation (EUA) from the US Food and Drug Administration (FDA). ... Regeneron has already signed a manufacturing and supply agreement with the US Biomedical Advanced
More from news
Approximately 0 fully matching, plus 23 partially matching documents found.
Latest Intelligence
-
Rethinking our approach to infectious disease preparedness
So we need long-term strategic investment so that we have therapies and vaccines under development – and the infrastructure to support them, from governments and the private sector – in the vital ... Achaogen and Aradigm filed for bankruptcy in 2019,
-
Developing a COVID-19 vaccine
The phase 1 study, which is being conducted by the US National Institutes of Health (NIH) at Kaiser Permanente Washington Health Research Institute in Seattle, aims to recruit 45 healthy men ... That includes an agreement with the US Biomedical Advanced
-
Deal Watch June 2016
One of the companies developing pathogen reduction systems for donated blood, Cerus Corporation, signed an agreement in June worth up to $180m with the US Biomedical Advanced Research and Development Authority ... Includes rights to sublicense outside
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
-
B2B media account director
-
Competitive salary
- AstraZeneca blocks take-private buyout of Sobi
- Lilly’s combination antibody expanded to children under 12
- Working with purpose and putting talent development at the heart of operations
- A Lucid Thirsty Thursday D&I Special
- Diversity in clinical trials: looking back at our 2021 blogs
- MHRA approves second COVID-19 antibody treatment
- First trial of a vaccine against Alzheimer’s launches
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS
- Pfizer's 2021 revenue predictions soar to $82bn
- Sinovac’s COVID-19 vaccine appears safe in older adults
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
PMHub
Graphite Digital
We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...
Latest intelligence
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
